Development of a New Solid-Phase Extraction Base Method for Free Saccharide Content Estimation of Meningococcal Conjugate Vaccines

[Image: see text] GlaxoSmithKline (GSK) is currently developing a fully liquid presentation to ease the administration of the licensed quadrivalent conjugate vaccine (Menveo) against meningococcal serogroup A, C, W, and Y (MenACWY) infections. Herein, we report a new method for determining the free...

Descripción completa

Detalles Bibliográficos
Autores principales: De Ricco, Riccardo, Rech, Francesca, Onnis, Valeria, Coccone, Salvatore Sanna, Scalia, Giusy, Marcozzi, Cristina, Gavini, Massimiliano, Beni, Sara, Giannini, Sara, Nompari, Luca, Parlati, Chiara, Magagnoli, Claudia, Cianetti, Simona, Berti, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9648139/
https://www.ncbi.nlm.nih.gov/pubmed/36385865
http://dx.doi.org/10.1021/acsomega.2c04013
Descripción
Sumario:[Image: see text] GlaxoSmithKline (GSK) is currently developing a fully liquid presentation to ease the administration of the licensed quadrivalent conjugate vaccine (Menveo) against meningococcal serogroup A, C, W, and Y (MenACWY) infections. Herein, we report a new method for determining the free saccharide (FS) content of CRM(197)-MenACWY conjugated antigens, with the aim of improving accuracy and reproducibility. Mathematical models have been used to support technical knowledge in reducing the need for experimental development. This results in an improved, faster, and platform-based technique for FS separation with one single pretreatment applicable to all antigens of the multivalent meningococcal vaccine.

Ejemplares similares